A detailed history of Rafferty Asset Management, LLC transactions in Biogen Inc. stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 160,201 shares of BIIB stock, worth $23.9 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
160,201
Previous 151,295 5.89%
Holding current value
$23.9 Million
Previous $35.1 Million 11.46%
% of portfolio
0.11%
Previous 0.13%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$189.07 - $236.8 $1.68 Million - $2.11 Million
8,906 Added 5.89%
160,201 $31.1 Million
Q2 2024

Aug 13, 2024

BUY
$190.52 - $236.72 $7.33 Million - $9.11 Million
38,479 Added 34.11%
151,295 $35.1 Million
Q1 2024

May 13, 2024

BUY
$212.02 - $267.71 $3.59 Million - $4.53 Million
16,934 Added 17.66%
112,816 $24.3 Million
Q4 2023

Feb 13, 2024

BUY
$222.59 - $267.94 $2.97 Million - $3.57 Million
13,335 Added 16.15%
95,882 $24.8 Million
Q3 2023

Nov 13, 2023

BUY
$253.3 - $285.89 $4.5 Million - $5.08 Million
17,754 Added 27.4%
82,547 $21.2 Million
Q2 2023

Aug 11, 2023

BUY
$275.25 - $318.06 $1.55 Million - $1.79 Million
5,628 Added 9.51%
64,793 $18.5 Million
Q1 2023

May 11, 2023

BUY
$256.56 - $292.34 $716,828 - $816,797
2,794 Added 4.96%
59,165 $16.4 Million
Q4 2022

Feb 13, 2023

SELL
$252.44 - $306.72 $4.15 Million - $5.05 Million
-16,459 Reduced 22.6%
56,371 $15.6 Million
Q3 2022

Nov 14, 2022

BUY
$194.69 - $268.46 $3.48 Million - $4.8 Million
17,895 Added 32.57%
72,830 $19.4 Million
Q2 2022

Aug 12, 2022

SELL
$187.54 - $223.02 $1.56 Million - $1.85 Million
-8,299 Reduced 13.12%
54,935 $11.2 Million
Q1 2022

May 13, 2022

BUY
$193.77 - $244.14 $3.54 Million - $4.46 Million
18,274 Added 40.65%
63,234 $13.3 Million
Q4 2021

Feb 10, 2022

BUY
$223.92 - $287.77 $3.54 Million - $4.54 Million
15,793 Added 54.15%
44,960 $10.8 Million
Q3 2021

Nov 10, 2021

BUY
$282.99 - $369.05 $2.75 Million - $3.59 Million
9,718 Added 49.97%
29,167 $8.25 Million
Q2 2021

Aug 10, 2021

SELL
$259.0 - $414.71 $2.5 Million - $4 Million
-9,647 Reduced 33.16%
19,449 $6.74 Million
Q1 2021

May 10, 2021

BUY
$242.95 - $284.63 $1.79 Million - $2.09 Million
7,355 Added 33.83%
29,096 $8.14 Million
Q4 2020

Feb 10, 2021

BUY
$236.26 - $355.63 $202,474 - $304,774
857 Added 4.1%
21,741 $5.32 Million
Q3 2020

Nov 13, 2020

BUY
$264.77 - $305.71 $745,327 - $860,573
2,815 Added 15.58%
20,884 $5.92 Million
Q2 2020

Aug 07, 2020

BUY
$258.66 - $342.55 $1.77 Million - $2.35 Million
6,856 Added 61.14%
18,069 $4.83 Million
Q1 2020

May 15, 2020

SELL
$268.85 - $341.04 $3.99 Million - $5.06 Million
-14,833 Reduced 56.95%
11,213 $3.55 Million
Q4 2019

Feb 10, 2020

SELL
$220.06 - $304.07 $2.34 Million - $3.23 Million
-10,611 Reduced 28.95%
26,046 $7.73 Million
Q3 2019

Nov 14, 2019

SELL
$217.44 - $243.88 $747,776 - $838,703
-3,439 Reduced 8.58%
36,657 $8.53 Million
Q2 2019

Aug 09, 2019

BUY
$219.29 - $241.72 $2.46 Million - $2.72 Million
11,237 Added 38.94%
40,096 $9.38 Million
Q1 2019

May 15, 2019

BUY
$216.71 - $338.96 $5.05 Million - $7.89 Million
23,281 Added 417.37%
28,859 $6.82 Million
Q4 2018

Feb 11, 2019

SELL
$278.5 - $352.75 $136,743 - $173,200
-491 Reduced 8.09%
5,578 $1.68 Million
Q3 2018

Nov 09, 2018

SELL
$293.51 - $383.83 $2.52 Million - $3.3 Million
-8,598 Reduced 58.62%
6,069 $2.14 Million
Q2 2018

Aug 14, 2018

BUY
$257.52 - $306.91 $1.48 Million - $1.77 Million
5,752 Added 64.52%
14,667 $4.26 Million
Q1 2018

May 15, 2018

BUY
$260.13 - $367.91 $1.14 Million - $1.61 Million
4,383 Added 96.71%
8,915 $2.44 Million
Q4 2017

Feb 14, 2018

SELL
$307.64 - $344.58 $103,059 - $115,434
-335 Reduced 6.88%
4,532 $1.44 Million
Q3 2017

Nov 13, 2017

BUY
$281.15 - $329.69 $1.37 Million - $1.6 Million
4,867
4,867 $1.52 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.5B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Rafferty Asset Management, LLC Portfolio

Follow Rafferty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.